The estimated Net Worth of Kristine Peterson is at least 558 千$ dollars as of 30 November 2023. Ms. Peterson owns over 20,000 units of Enanta Pharmaceuticals Inc stock worth over 240,800$ and over the last 12 years she sold ENTA stock worth over 0$. In addition, she makes 316,997$ as Independent Director at Enanta Pharmaceuticals Inc.
Kristine has made over 3 trades of the Enanta Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 20,000 units of ENTA stock worth 231,800$ on 30 November 2023.
The largest trade she's ever made was exercising 20,000 units of Enanta Pharmaceuticals Inc stock on 30 November 2023 worth over 231,800$. On average, Kristine trades about 1,111 units every 39 days since 2012. As of 30 November 2023 she still owns at least 20,000 units of Enanta Pharmaceuticals Inc stock.
You can see the complete history of Ms. Peterson stock trades at the bottom of the page.
Kristine Peterson is Independent Director of the Company. Ms. Peterson has over 25 years of senior executive experience in commercial and business leadership roles in the pharmaceutical and biotechnology industry. From 2009 to 2016, Ms. Peterson served as Chief Executive Officer of Valeritas, Inc., a commercial-stage medical technology company where, under her leadership, the organization evolved from a research stage company to a commercial enterprise. Previously she held executive global marketing and commercial roles at Johnson & Johnson from 2004 to 2009, most recently as Company Group Chair, Biotech Sector, where she was responsible for commercial, R&D, and biologics manufacturing for biotech, oncology, immunology and cell therapy. From 2003 to 2004, she served as Senior Vice President, Commercial Operations for Biovail Corporation and President of Biovail Pharmaceuticals. Earlier in her career, she spent 20 years at Bristol-Myers Squibb Company in senior sales and marketing roles of increasing responsibility in a broad range of therapeutic areas that included Cardiovascular, Metabolic, Anti-infective, Virology, Neuroscience, Immunology/Inflammation, Pulmonary, and Oncology. Ms. Peterson currently serves on the Boards of Directors of Amarin Corporation plc, ImmunoGen, Inc., Paratek Pharmaceuticals, Inc. and EyePoint Pharmaceuticals, Inc., all of which are public biopharmaceutical companies. She received a Master of Business Administration and a Bachelor of Science from the University of Illinois at Urbana-Champaign.
As the Independent Director of Enanta Pharmaceuticals Inc, the total compensation of Kristine Peterson at Enanta Pharmaceuticals Inc is 316,997$. There are 14 executives at Enanta Pharmaceuticals Inc getting paid more, with Jay Luly having the highest compensation of 4,483,500$.
Kristine Peterson is 60, she's been the Independent Director of Enanta Pharmaceuticals Inc since 2017. There are 10 older and 5 younger executives at Enanta Pharmaceuticals Inc. The oldest executive at Enanta Pharmaceuticals Inc is Bruce Carter, 76, who is the Independent Non-Executive Chairman of the Board.
Kristine's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.
Over the last 12 years, insiders at Enanta Pharmaceuticals Inc have traded over 72,640,961$ worth of Enanta Pharmaceuticals Inc stock and bought 354,891 units worth 5,071,651$ . The most active insiders traders include Jay R. Luly、V Life Science Ventures Gmb...、Yat Sun Or. On average, Enanta Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of 285,155$. The most recent stock trade was executed by Scott T. Rottinghaus on 11 July 2024, trading 11,945 units of ENTA stock currently worth 190,762$.
enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.
Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include: